ReviewNeurology. Clinical practice2017
Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.
Review in Neurology. Clinical practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology.Journal of neurology · 2024Guideline
- Treatment of Parkinson's Disease-Related Psychosis.Clinical pharmacology : advances and applications · 2026Review
- Real-world evidence of pimavanserin utilization among patients with Parkinson's disease psychosis: a review of real-world data that augments data from randomized controlled trials.Journal of comparative effectiveness research · 2025Review
- Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.Schizophrenia bulletin · 2025Review
- Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review.Journal of the Chinese Medical Association : JCMA · 2024Review
- Fountain of youth-Targeting autophagy in aging.Frontiers in aging neuroscience · 2023Review
- Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review.Brain sciences · 2022Review
- Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome.Movement disorders clinical practice · 2021Article
- Update on Major Neurocognitive Disorders.Focus (American Psychiatric Publishing) · 2021Article
- Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access.The mental health clinician · 2021Article
- Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.Parkinson's disease · 2021Article
- Clinical drug development for dementia with Lewy bodies: past and present.Expert opinion on investigational drugs · 2019Review
- Pharmacological Management of Dementia with Lewy Bodies.Drugs & aging · 2019Review
- Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.Movement disorders : official journal of the Movement Disorder Society · 2019Review
- Author response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.Neurology. Clinical practice · 2018Article
- Reader response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.Neurology. Clinical practice · 2018Article
- Delusional Jealousy (Othello Syndrome) in 67 Patients with Parkinson's Disease.Frontiers in neurology · 2018Review
- Erratum: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.Neurology. Clinical practice · 2017Article
- Neurology and mental health.Neurology. Clinical practice · 2017Article
- Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials.Innovations in clinical neuroscienceReview
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn April 2016, the Food and Drug Administration (FDA) approved a first-in-class atypical antipsychotic medication called pimavanserin for the treatment of Parkinson disease psychosis (PDP). We aim to inform readers about its indications, effectiveness, and safety profile. RECENT
findingsPimavanserin acts as an inverse agonist at serotonin 5-HT2A receptors and has negligible effects on other receptors, thereby avoiding the D2 receptor antagonism that can potentially worsen motor symptoms. Its FDA approval was based primarily on the results of a single randomized, placebo-controlled phase 3 trial. SUMMARY: While pimavanserin appears to be a safe, effective, and well-tolerated therapeutic option for PDP, additional clinical trials and open-label extension studies are needed to determine the long-term safety and efficacy of this promising therapy. In the meantime, prescribers need to be aware of the possible adverse effects of pimavanserin including QT interval prolongation and a potential to cause a paradoxical worsening of symptoms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.